Tackling the challenges of patients with skin condition

Chronic skin conditions affect nearly 3 billion people worldwide — yet adherence remains the industry's biggest blind spot, with non-adherence rates in dermatology outpacing diabetes, asthma, and even hypertension.

See how Observia partners with leading pharma companies, patient associations, and dermatologists to turn behavioral science and digital health into measurable patient outcomes.

Our track-record document brings together four of Observia's flagship dermatology projects, from patient studies to fully deployed digital support platforms, showing exactly how we help pharma teams close the gap between prescription and real-life patient behavior.

What you'll find inside

• Atopic Dermatitis patient study — how photo-elicitation interviews uncovered the emotional drivers behind biotherapy adoption
• Acne adherence research with La Roche-Posay (L'Oréal) — a 500-respondent behavioral segmentation revealing why 94% of patients were at high risk of non-adherence
• A scalable Patient Support Program for a rare skin condition — 9 features, an 18-week AI-personalized engagement plan, and an NPS of 60 from pilot patients
• CaliPso: chatbot + patient platform for psoriasis, built with France Psoriasis association and Lilly — 10,700+ chatbot conversations and 83% user satisfaction

Download the full track record
Get the complete PDF with all 4 business cases, methodology deep-dives, and results — free.